Percutaneous Closure of the Patent Ductus Arteriosus in Very Low Weight Infants: Considerations Following US Food and Drug Administration Approval of a Novel Device

The Amplatzer Piccolo  Occluder (or Amplatzer duct occluder II-additional sizes, ADO-II AS, Abbott, Chicago, Illinois) was approved by the US Food and Drug Administration on January 11, 2019.1 The class III device is indicated for percutaneous (catheter-based) closure of a patent ductus arteriosus (PDA) in an infant wei ghing>700  grams and a postnatal age of>3  days. After this regulatory approval, the healthcare community is tasked with answering fundamental questions on the appropriate use of the device in a subgroup of highly vulnerable patients.
Source: The Journal of Pediatrics - Category: Pediatrics Authors: Tags: Commentary Source Type: research